GSK sues Moderna for US patent infringement over COVID, RSV vaccines
Source: Yahoo! Finance/Reuters
Updated Tue, October 15, 2024 at 5:15 PM EDT
(Reuters) -British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing it of violating GSK patent rights in messenger RNA technology with its blockbuster COVID-19 vaccine Spikevax and RSV shot mResvia.
According to the two lawsuits, Moderna's lipid nanoparticles for transporting fragile mRNA into the human body infringe several GSK patents covering similar innovations. GSK filed a related lawsuit against Pfizer and BioNTech in the same court in April over their COVID-19 vaccine. The new litigation seeks unspecified monetary damages.
A spokesperson for Massachusetts-based Moderna said the company was aware of the lawsuits and would defend itself against the claims. GSK is "willing to license these patents on commercially reasonable terms and to ensure continued patient access," a company spokesperson said.
The lawsuits add to a web of U.S. court cases involving Pfizer, BioNTech and Moderna over patent royalties for technology used in their COVID vaccines, including one brought by Moderna against Pfizer in 2022.
Read more: https://finance.yahoo.com/news/glaxosmithkline-sues-moderna-us-patent-142032509.html